How has this study helped patients and researchers?
More than half of the patients who took part in the study had a complete response to treatment
with ravulizumab. Patients also reported an improvement in their quality of life, including a
reduction in fatigue, which is a disabling symptom of aHUS.
Ravulizumab is an approved treatment for aHUS in some countries.
If you have any questions about ravulizumab for the treatment of aHUS,
please talk to your doctor. You should not change your treatment based
on the results of this study without talking to a doctor first.
MORE INFORMATION
Useful clinical study websites
This document provides a summary of the main results of the study. It includes answers to the
questions the researchers had and information about the adverse events experienced by patients
when treated with ravulizumab.
A full report may be available to read at one of the following clinical trial registers:
www.clinicaltrials.gov
Use the study number NCT02949128 to search for more information on
this website.
www.clinicaltrialsregister.eu
Use the study number 2016-002027-29 to search for more information on
this website.
Further studies
For more information about other studies investigating ravulizumab for the treatment of diseases
where the immune system attacks healthy parts of the body, please follow the links below.
ALXN1210-TMA-313, Ravulizumab in Thrombotic Microangiopathy After Hematopoietic
Stem Cell Transplant
ALXN1210-TMA-314, Ravulizumab in Children with Thrombotic Microangiopathy After Hematopoietic
Stem Cell Transplantation
Protocol, ALXN1210-aHUS-311 SPONSOR CONTACT INFORMATION:
Europe, 2016-002027-29 1-888-765-4747
Â© Certara USA, Inc. 2020. All rights reserved United States, NCT02949128 medinfo@alexion.com 11